2025
Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
Xu H, Aparicio C, Wats A, Araujo B, Pitzer V, Warren J, Shapiro E, Niccolai L, Weinberger D, Oliveira C. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Network Open 2025, 8: e250380. PMID: 40063022, PMCID: PMC11894488, DOI: 10.1001/jamanetworkopen.2025.0380.Peer-Reviewed Original ResearchConceptsRSV-positive casesCase-control studyRSV infectionLRTI-associated hospitalizationsWeeks postimmunizationLong-acting monoclonal antibodiesTest-negative case-control studyClinical settingRespiratory syncytial virusMultivariate logistic regressionYale New Haven Health SystemRSV diseaseEmergency department dataState immunization registryRSV seasonSyncytial virusNirsevimabPolymerase chain reactionClinical trialsLRTIInfantsPotential confoundersMonoclonal antibodiesBroader outcomesDisease severity
2024
Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV
Prunas O, Willemsen J, Warren J, Bont L, Schwartz J, Atwell J, Begier E, Dean N, Hirsch I, Karron R, Klugman K, Kramer R, Leidman E, Link-Gelles R, Nair H, Panozzo C, Pelfrene E, Simões E, Smith P, Srikantiah P, Sundaram M, Thindwa D, Vaughn D, Wilson E, Zar H, Pitzer V, Weinberger D. Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV. Vaccine X 2024, 19: 100509. DOI: 10.1016/j.jvacx.2024.100509.Peer-Reviewed Original ResearchRespiratory syncytial virusRandomized controlled trialsPreventive therapyPrevention of respiratory syncytial virusTrial designSuccess of randomized controlled trialsVaccine trial designDesign randomized controlled trialClinical trial designEstimates of vaccine efficacyPrimary endpointSyncytial virusClinical trialsVaccine efficacyControlled trialsMeta-regression modelsSelection of primary endpointsEndpointSequential trial designTherapyMultiple endpoints
2023
Typhoid fever
Meiring J, Khanam F, Basnyat B, Charles R, Crump J, Debellut F, Holt K, Kariuki S, Mugisha E, Neuzil K, Parry C, Pitzer V, Pollard A, Qadri F, Gordon M. Typhoid fever. Nature Reviews Disease Primers 2023, 9: 71. PMID: 38097589, DOI: 10.1038/s41572-023-00480-z.Peer-Reviewed Original ResearchConceptsTyphoid feverUndifferentiated febrile illnessInvasive bacterial diseaseEffective vaccination programsFecal-oral routeNovel diagnostic modalitiesFebrile illnessBloodstream infectionsVaccination programBlood culturesClinical trialsImmunological protectionHigh burdenCausative organismDiagnostic modalitiesGlobal burdenDisease pathogenesisFeverHuman infectionsIntestinal epitheliumYoung adultsCulture testingSalmonella enterica subspSerovar TyphiAntimicrobial resistance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply